about
Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactionsOmeprazole and lansoprazole enantiomers induce CYP3A4 in human hepatocytes and cell lines via glucocorticoid receptor and pregnane X receptor axisEvaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects.Differential effects of omeprazole and lansoprazole enantiomers on aryl hydrocarbon receptor in human hepatocytes and cell lines.A fluorescence-based high throughput assay for the determination of small molecule-human serum albumin protein binding.Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity.In vitro study of the variable effects of proton pump inhibitors on voriconazoleLiver-stage malaria parasites vulnerable to diverse chemical scaffolds.Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions.The stereoselectivity of CYP2C19 on R- and S-isomers of proton pump inhibitors.Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.Hydroxylation of R(+)- and S(-)-omeprazole after racemic dosing are different among the CYP2C19 genotypes.Studies on the enantiomers of ZJM-289: synthesis and biological evaluation of antiplatelet, antithrombotic and neuroprotective activities.Single enantiomer versus racemate: chiral distinction in the proton pump inhibitors omeprazole and esomeprazole.Solid-phase extraction combined with dispersive liquid-liquid microextraction and chiral liquid chromatography-tandem mass spectrometry for the simultaneous enantioselective determination of representative proton-pump inhibitors in water samples.Safe use of proton pump inhibitors in patients with cirrhosis.Efficacy of S-Pantoprazole 20 mg Compared with Pantoprazole 40 mg in the Treatment of Reflux Esophagitis: A Randomized, Double-Blind Comparative Trial
P2860
Q24611315-76917011-D767-417B-92E6-ECFE5067990BQ28542441-E9E115B5-4B61-4E7C-8E0B-60D2E8D1EFC6Q33448993-9F87996B-0B21-4C16-A54A-3924ECBBF5C3Q33700433-1FF8EDEC-4C22-4E9C-B231-F7011AF8CDCEQ35081931-EB3CC7A3-6D7E-4DDC-AC16-F3C66064CFA4Q35537682-C757BE5A-29DA-4C14-AA09-E5B4E8B045F7Q35960842-371E7357-E5B3-4A82-84C2-B39DDF6385EDQ36001246-0AF2D857-4D2E-45A9-9176-EB9DE34DC2E6Q36653603-FCC5490D-0B78-44A0-9BFD-AA9498AEA356Q36887128-C2B24321-09F2-4A45-85B3-C0CF4F81565BQ37086418-B07E5785-B7D6-4D81-84BE-75E44A98502AQ37162141-098DE2F2-7013-4593-A14A-C9E782926F95Q38907268-349DA57E-BE21-45A7-AA48-FDB34A950F80Q39240124-49FDC18B-A77D-4331-928E-EB030999ABE5Q39292057-82D9B374-AF27-4919-996B-F2F442358FACQ42907834-EFC44DC5-2DA4-4EFB-95C2-265A20C689F9Q44149312-2FE61A3A-38C8-4BB7-9A6A-03294612E4D2Q44990286-7E96FF62-3CD9-42A3-B2C3-17DF7CA331D7Q48332206-E1BB698A-F350-4898-89F4-74D15468D736Q48881458-02DC6FF0-5A7A-4B03-A770-0C52CF2E2DDAQ51236069-F7973ED4-187B-4958-A4E4-7D2B1AAD4430Q55718075-F09DD705-2DE9-4846-B750-7D689EB61136Q57728317-E541A71A-6541-40E7-93DB-BF24D4B8D1AD
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Stereoselective disposition of proton pump inhibitors.
@en
Stereoselective disposition of proton pump inhibitors.
@nl
type
label
Stereoselective disposition of proton pump inhibitors.
@en
Stereoselective disposition of proton pump inhibitors.
@nl
prefLabel
Stereoselective disposition of proton pump inhibitors.
@en
Stereoselective disposition of proton pump inhibitors.
@nl
P2860
P1476
Stereoselective disposition of proton pump inhibitors.
@en
P2093
Lars Weidolf
Tommy Andersson
P2860
P304
P356
10.2165/00044011-200828050-00001
P577
2008-01-01T00:00:00Z